X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan Sells 31,897 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 31,897 shares of X4 Pharmaceuticals stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $0.56, for a total value of $17,862.32. Following the transaction, the chief executive officer now owns 1,025,816 shares of the company’s stock, valued at $574,456.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Paula Ragan also recently made the following trade(s):

• On Monday, October 7th, Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.53 on Thursday. The business has a fifty day moving average of $0.66 and a 200 day moving average of $0.86. X4 Pharmaceuticals, Inc. has a one year low of $0.47 and a one year high of $1.60. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. The firm has a market capitalization of $89.51 million, a P/E ratio of -0.76 and a beta of 0.36.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The company had revenue of $0.56 million during the quarter, compared to the consensus estimate of $52.98 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. As a group, sell-side analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. K2 Principal Fund L.P. purchased a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $284,000. AQR Capital Management LLC grew its stake in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in X4 Pharmaceuticals by 39.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after acquiring an additional 133,398 shares during the last quarter. XTX Topco Ltd bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at about $65,000. Finally, Ensign Peak Advisors Inc grew its position in shares of X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of X4 Pharmaceuticals in a research report on Friday, June 28th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.